IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Login

Citations for " The Changing Rewards to Science: The Case of Biotechnology"

by Stephan, Paula E & Everhart, Stephen S

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. Michael R. Darby & Lynne G. Zucker, 2002. "Going Public When You Can in Biotechnology," NBER Working Papers 8954, National Bureau of Economic Research, Inc.
  2. David Catherine & Frédéric Corolleur & Myriam Carrère & Vincent Mangematin, 2004. "Turning scientific and technological human capital into economic capital: the experience of biotech start-ups in France," Grenoble Ecole de Management (Post-Print) hal-00422583, HAL.
  3. Lynne G. Zucker & Michael R. Darby & Jeff S. Armstrong, 2003. "Commercializing knowledge: university science, knowledge capture and firm performance in biotechnology," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 149-170.
  4. Nicola Lacetera, 2003. "Incentives and spillovers in R&D activities: an agency-theoretic analysis of industry-university relations," Microeconomics 0312004, EconWPA.
  5. C. Thomas Caskey, 2003. "The convergence of disruptive technologies enabling a new industrial approach to health products," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 77-84.
  6. Michael R. Darby & Lynne G. Zucker, 2002. "Growing by Leaps and Inches: Creative Destruction, Real Cost Reduction, and Inching Up," NBER Working Papers 8947, National Bureau of Economic Research, Inc.
  7. Tetsugen Haruyama, 2009. "Competitive Innovation with Codified And Tacit Knowledge," Discussion Papers 0905, Graduate School of Economics, Kobe University.
  8. Timothy F. Howe, 2003. "Financing biotechnology research: a firsthand perspective," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 119-130.
  9. John V. Duca & Mine K. Yücel, 2003. "Science and Cents: Exploring the economics of biotechnology: an overview," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 3-10.
  10. Frank R. Lichtenberg, 2003. "The benefits to society of new drugs: a survey of the econometric evidence," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 43-59.
  11. Lam, Alice, 2011. "What motivates academic scientists to engage in research commercialization: ‘Gold’, ‘ribbon’ or ‘puzzle’?," Research Policy, Elsevier, vol. 40(10), pages 1354-1368.
  12. Malcolm Gillis, 2003. "Harnessing new technologies for the 21st century," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 63-75.
  13. Nicolaou, Nicos & Birley, Sue, 2003. "Academic networks in a trichotomous categorisation of university spinouts," Journal of Business Venturing, Elsevier, vol. 18(3), pages 333-359, May.
  14. Ding, Waverly & Choi, Emily, 2011. "Divergent paths to commercial science: A comparison of scientists' founding and advising activities," Research Policy, Elsevier, vol. 40(1), pages 69-80, February.
  15. Henry G. Grabowski, 2003. "Patents and new product development in the pharmaceutical and biotechnology industries," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 87-104.
  16. Chok, Jay Inghwee, 2009. "Regulatory dependence and Scientific Advisory Boards," Research Policy, Elsevier, vol. 38(5), pages 710-725, June.
  17. Michael S. Lawlor, 2003. "Biotechnology and government funding: economic motivation and policy models," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 131-146.
  18. Luo, Xiaowei Rose & Koput, Kenneth W. & Powell, Walter W., 2009. "Intellectual capital or signal? The effects of scientists on alliance formation in knowledge-intensive industries," Research Policy, Elsevier, vol. 38(8), pages 1313-1325, October.
  19. Rebecca S. Eisenberg, 2003. "Reaching through the genome," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 105-115.
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.